Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 6463
Encontrada(s) 647 página(s)
idUS. Depósito de Investigación de la Universidad de Sevilla
oai:idus.us.es:11441/167278
Datos de investigación Set de datos (Dataset)

Neuromorphic Audio for Predictive Maintenance in Peristaltic Pumps [Dataset]

Audio neuromórfico para mantenimiento predictivo en bombas peristálticas [Dataset]
  • Montes-Sánchez, Juan Manuel
  • Domínguez Morales, Juan Pedro
  • Vicente Díaz, Saturnino
  • Jiménez Fernández, Ángel Francisco
This dataset contains processed audio samples coming from a hydraulic block from a biomedical equipment. The block mounts 3 Thomas SR10/30 DC standard perisltaltic pumps, which were filled with distilled water. Only one pump was running at the same time during these recordings. There are two different predictive maintenance scenarios. In the first one, the cassettes of the pumps were changed before each recording. We used cassettes with 2 different levels of degradation: NEW (unused) and OLD (lifetime already expired). We defined 3 different classes: Class 1 is STOP (no pump running), class 2 is NEW (one pump running with a new cassette), and class 3 is OLD (one pump running with an old cassette). In the second scenario, air bubbles were introduced into the tube. This second scenario also has 3 classes: Class 1 is STOP (no pump running), class 2 is NORMAL (no air bubbles), and class 3 is BUBBLE (air bubbles present). A single microphone was used for all recordings. The .wav audio files were processed using a 64 channel Neuromorphic Auditory Sensor (NAS) into .aedat files, which are the present in this dataset. This neuromorphic audio data were also converted into cochleogram images using the software pyNAVIS, and they are also present in this format (.png files)., There is one folder for each of the two scenarios (aging and bubble). Inside those folders there are 3 subfolders, one for each data type (AEDAT, PNG and WAV). For WAV and AEDAT, each file is a unique sample tagged with one class (1, 2 or 3). At the end of each filename this class is also included. For example, 0008_03.wav is the sample number 8, which corresponds to class 3 tagged data. PNG cochleogram images represent 500ms audio time each and are named after their source AEDAT file followed by their starting time mark in microseconds.
RIUMA. Repositorio Institucional de la Universidad de Málaga
oai:riuma.uma.es:10630/39576
Datos de investigación Sonido (Sound)

Relaciones Públicas y Desinformación

  • VV.AA.
Cómo citar: Oliveira, Andrea; Zeler, Ileana & Ruiz-Mora,Isabel (Coord.). (2025, junio 02). Relaciones Públicas y Desinformación (No3) [Episodio de Audio Podcast.] En Relaciones Públicas al Descubierto., Descubre, con María-Isabel Míguez-González (Profesora Titular en el departamento de Comunicación Audiovisual y Publicidad en la Universidade de Vigo y grupo de investigación en comunicación para el servicio público (SEPCOM), María Laura García (Presidenta del Comité Empresarial del World Innovation and Change Management Institute ) y Leticia Rodríguez Fernández (Profesora Titular en el Departamento de Marketing y Comunicación y directora general de Comunicación Estratégica en la Universidad de Cádiz), cómo las Relaciones Públicas pueden ayudar a la sociedad a afrontar el reto de la desinformación con una visión crítica y prospectiva, Asociación de Investigadores en Relaciones Públicas (AIRP)
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/28472
Publicación Otros (Other)

Proceso respiratorio: Agudización de la EPOC_0

  • Lopez-Lopez C
  • Luque-Hernandez MJ
  • Gomez Parra S
AGUDIZACIÓN DE LA EPOC (AEPOC), La Agudización de la Enfermedad Pulmonar Obstructiva Crónica (AEPOC) se define según la GesEPOC 2021 como un “episodio de inestabilidad clínica en un paciente EPOC como consecuencia del agravamiento de la limitación espiratoria al flujo aéreo o del proceso inflamatorio subyacente y se caracteriza por un empeoramiento agudo de los síntomas respiratorios respecto de la situación basal del individuo”., Yes
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/30868
Publicación Otros (Other)

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

  • Van Laethem, Jean-Luc
  • Geboes, Karen
  • Borbath, Ivan
  • Macarulla Mercade, Teresa
  • Lambert, Aurelien
  • Cassier, Philippe
  • Prenen, Hans
  • Mitry, Emmanuel
  • Blanc, Jean-Frederic
  • Pilla, Lorenzo
  • Feliu, Jaime
  • Rodriguez Garrote, Mercedes
  • Pazo-Cid, Roberto Antonio
  • Gallego, Inmaculada
  • Smith, Karin Enell
  • Nordbladh, Karin
  • Jimenez, David Gomez
  • Ellmark, Peter
  • Pico de Coaña, Yago
  • Ambarkhane, Sumeet Vijay
  • Beatty, Gregory L
  • O'Reilly, Eileen M
Response determinants to immunotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) remain unclear, limiting treatment advancements. We report a single-arm phase 1b/2 study (OPTIMIZE-1) evaluating the safety and efficacy of the cluster of differentiation 40 (CD40) agonist mitazalimab combined with modified FOLFIRINOX (mFOLFIRINOX), in chemotherapy-naive patients with mPDAC. Patients receive an initial dose of mitazalimab one week before starting biweekly cycles of mFOLFIRINOX plus mitazalimab. The study meets its pre-specified primary endpoint, achieving a confirmed objective response rate (ORR) of 42.1%. Median duration of response, progression-free survival, and overall survival was 12.6 months, 7.7 months, and 14.9 months, respectively. Multi-omic analyses of tumor and blood specimens identify a baseline tumor-intrinsic gene signature related to fibrosis associated with improved survival. Additionally, mitazalimab-induced increases in activated circulating myeloid, B cell, and T cell frequencies correlate with better outcomes. These results may inform future patient stratification strategies supporting a planned randomized confirmatory trial of mitazalimab with mFOLFIRINOX in mPDAC. This study was registered at ClinicalTrials.gov (NCT04888312)., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/26962
Publicación Otros (Other)

Metabolomics of the tryptophan-kynurenine degradation pathway and risk of atrial fibrillation and heart failure: potential modification effect of Mediterranean diet.

  • Razquin, Cristina
  • Ruiz-Canela, Miguel
  • Toledo, Estefania
  • Hernández-Alonso, Pablo
  • Clish, Clary B
  • Guasch-Ferré, Marta
  • Li, Jun
  • Wittenbecher, Clemens
  • Dennis, Courtney
  • Alonso-Gómez, Angel
  • Fitó, Montse
  • Liang, Liming
  • Corella, Dolores
  • Gómez-Gracia, Enrique
  • Estruch, Ramon
  • Fiol, Miquel
  • Lapetra, Jose
  • Serra-Majem, Lluis
  • Ros, Emilio
  • Aros, Fernando
  • Salas-Salvadó, Jordi
  • Hu, Frank B
  • Martínez-González, Miguel A
The tryptophan-kynurenine pathway is linked to inflammation. We hypothesize that metabolites implicated in this pathway may be associated with the risk of heart failure (HF) or atrial fibrillation (AF) in a population at high risk of cardiovascular disease. We aimed to prospectively analyze the associations of kynurenine-related metabolites with the risk of HF and AF and to analyze a potential effect modification by the randomized interventions of the PREDIMED (Prevención con Dieta Mediterránea) trial with Mediterranean diet (MedDiet). Two case-control studies nested within the PREDIMED trial were designed. We selected 324 incident HF cases and 502 incident AF cases individually matched with ≤3 controls. Conditional logistic regression models were fitted. Interactions with the intervention were tested for each of the baseline plasma metabolites measured by LC-tandem MS. Higher baseline kynurenine:tryptophan ratio (OR for 1 SD: 1.20; 95% CI: 1.01, 1.43) and higher levels of kynurenic acid (OR: 1.19; 95% CI: 1.01, 1.40) were associated with HF. Quinolinic acid was associated with AF (OR: 1.15; 95% CI: 1.01, 1.32) and HF (OR: 1.25; 95% CI: 1.04, 1.49). The MedDiet intervention modified the positive associations of kynurenine (Pinteraction = 0.006), kynurenic acid (Pinteraction = 0.008), and quinolinic acid (Pinteraction = 0.033) with HF and the association between kynurenic acid and AF (Pinteraction = 0.02). We found that tryptophan-kynurenine pathway metabolites were prospectively associated with higher HF risk and to a lesser extent with AF risk. Moreover, an effect modification by MedDiet was observed for the association between plasma baseline kynurenine-related metabolites and the risk of HF, showing that the positive association of increased levels of these metabolites and HF was restricted to the control group., Sí
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/26965
Publicación Otros (Other)

A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial

  • Sanllorente, Albert
  • Soria-Florido, Maria Trinidad
  • Castaner, Olga
  • Lassale, Camille
  • Salas-Salvado, Jordi
  • Martinez-Gonzalez, Miguel Angel
  • Subirana, Isaac
  • Ros, Emilio
  • Corella, Dolores
  • Estruch, Ramon
  • Tinahones, Francisco J.
  • Hernaez, Alvaro
  • Fito, Montserrat
Background: Consumption of a Mediterranean diet, adequate levels of physical activity, and energy-restricted lifestyle interventions have been individually associated with improvements in HDL functions. Evidence of intensive interventions with calorie restriction and physical activity is, however, scarce. Objectives: To determine whether an intensive lifestyle intervention with an energy-restricted Mediterranean diet plus physical activity enhanced HDL function compared to a non-hypocaloric Mediterranean eating pattern without physical activity. Methods: In 391 older adults with metabolic syndrome (mean age, 65 years; mean BMI, 33.3 kg/m2) from 1 of the Prevención con Dieta Mediterránea-Plus trial centers, we evaluated the impact of a 6-month intervention with an energy-restricted Mediterranean diet plus physical activity (intensive lifestyle; n = 190) relative to a nonrestrictive Mediterranean diet without physical activity (control; n = 201) on a set of HDL functional traits. These included cholesterol efflux capacity, HDL oxidative/inflammatory index, HDL oxidation, and levels of complement component 3, serum amyloid A, sphingosine-1-phosphate, triglycerides, and apolipoproteins A-I, A-IV, C-III, and E in apoB-depleted plasma. Results: The intensive-lifestyle intervention participants displayed greater 6-month weight reductions (-3.83 kg; 95% CI: -4.57 to -3.09 kg) but no changes in HDL cholesterol compared with control-diet participants. Regarding HDL functional traits, the intensive lifestyle decreased triglyceride levels (-0.15 mg/g protein; 95% CI: -0.29 to -0.014 mg/g protein) and apoC-III (-0.11 mg/g protein; 95% CI: -0.18 to -0.026 mg/g protein) compared to the control diet, with weight loss being the essential mediator (proportions of mediation were 77.4% and 72.1% for triglycerides and apoC-III levels in HDL, respectively). Conclusions: In older adults with metabolic syndrome, an energy-restricted Mediterranean diet plus physical activity improved the HDL triglyceride metabolism compared with a nonrestrictive Mediterranean diet without physical activity. This trial is registered at isrctn.com as ISRCTN89898870., This work was supported by the Instituto de Salud Carlos III (grant numbers: CB06/03/0028, CD17/00122, IFI16/00012, PI15/00047, PI18/00020, and P19/00017), Fundació La Marató de TV3 (grant number: 201512.31), Agència de Gestió d’Ajuts Universitaris i de Recerca (grant number: 2017 BP 00021, 2017 SGR 222, SLT002/16/00088), and the European Regional Development Fund., Sí
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/28458
Publicación Otros (Other)

Description of basic competencies in clinical ultrasound imaging for emergency departments

Competencias básicas de la ecografía clínica en los servicios de urgencias y emergencias
  • Villegas-Villegas, Tomas
  • Campo-Linares, Ricardo
  • Alonso-Viladot, Jose-Ramon
  • Martinez-Mas, Roser
  • Luque-Hernandez, Maria-Jose
  • Ruiz-Duran, Miriam
  • Oviedo-Garcia, Alberto
  • Alvarez-Gregori, Jose-Antonio
  • Aguilar-Mulet, Mariano
  • Campos-Caubet, Luis
  • Cardenas-Bravo, Linder
  • Chaparro-Pardo, David
  • Chehayed-Moran, Jaldun
  • Esteban-Velasco, Jose-Vicente
  • Ferreiro-Gomez, Manuel
  • Garcia-Martin, Daniel
  • Garcia-Suarez, Ivan
  • Martinez-Hernandez, Adrian
  • Hernandez-Galan, Angel
  • Millan-Soria, Javier
  • Martienz-Lopez, Jose-Felix
  • Rodriguez-Garcia, Jose-Francisco
  • Ruano-Pena. Ines
  • Salvador-Suarez, Francisco-Jose
  • Simo-Melendez, Susana
  • Zafra-Sanchez, Juan-Jose
  • Nogue-Bou, Ramon
Recent years have seen great advances in the use of clinical ultrasound imaging in both hospital emergency departments and out-of-hospital settings. However, all new techniques require up-to-date definitions of competencies relevant to the clinical realities of different specialties and the geographic settings in which specialists work. To that end, a group of experts in clinical ultrasound reviewed the evidence available in the literature and strictly applied the Delphi method to define the competencies relevant to emergency physicians. The group worked with the starting premise that clinical ultrasound imaging should be a common competency across the specialty., En los últimos años se han producido grandes avances en el uso de la ecografía clínica tanto en los servicios de urgencias hospitalarios como en el ámbito extrahospitalario. Sin embargo, toda nueva técnica requiere de definiciones actualizadas de competencias relevantes para las realidades clínicas de las diferentes especialidades y los entornos geográficos en los que trabajan los especialistas. Para ello, un grupo de expertos en ecografía clínica revisó la evidencia disponible en la literatura y aplicó estrictamente el método Delphi para definir las competencias relevantes para los médicos de urgencias. El grupo trabajó con la premisa de partida de que la ecografía clínica debería ser una competencia común para toda la especialidad., Yes
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/30689
Publicación Otros (Other)

Three types of ligamentum flavum resections for the treatment of lumbar central canal stenosis: BUTTERFLY retrospective study.

  • Kaen, Ariel
  • Rocha Romero, Santiago
  • Correa Romero, Maria Jesus
  • Durand, Fernando
  • Martin, Ignacio
Retrospective analysis of a prospective study. The study aimed to evaluate and compare the clinical results of three surgical techniques for the resection of the hypertrophic ligamentum flavum in patients with lumbar stenosis. Lumbar spinal stenosis is a common degenerative condition. Biportal endoscopic surgery is a modern technique that has gained popularity in recent years. Although various techniques have been proposed for resecting the ligament, no studies have identified the most superior method. This retrospective study enrolled patients with severe lumbar canal stenosis who underwent biportal endoscopic "Z" technique decompression between 2021 and 2023. Patients with any clinical or radiological signs of spondylolisthesis were excluded. The resection of the ligamentum flavum was classified into piecemeal resection, one-piece "butterfly" resection, and the novel variant "two-wings" or two-piece resection. Several demographic and clinical statistical variables were collected, with a specific focus on surgical time, postoperative complications, and clinical outcomes. Ninety lumbar decompression surgeries were performed on 70 patients. The patients were divided into the butterfly group (en bloc) with 27 levels, "two-wings" group with 35 levels, and "piecemeal" group with 28 levels. No significant differences in demographics or clinical variables were found among the three groups. However, piecemeal resection was associated with a higher incidence of dural tears and a longer surgical time (p The results revealed that removing the ligamentum flavum en bloc (either in two pieces or one) may reduce the surgical time and incidence of dural tears. Randomized and prospective studies are warranted to establish definitive conclusions., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/31390
Publicación Otros (Other)

Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, B. infantis LMG11588, and B. lactis CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial

  • Picaud, Jean-Charles
  • Claris, Olivier
  • Gil-Campos, Mercedes
  • Salamanca de la Cueva, Ignacio
  • Cornette, Luc
  • Alliet, Philippe
  • Leke, Andre
  • Castanet, Mireille
  • Piloquet, Hugues
  • de Halleux, Virginie
  • Mitanchez, Delphine
  • Vandenplas, Yvan
  • Maton, Pierre
  • Jochum, Frank
  • Olbertz, Dirk
  • Negre Policarpo, Sergio
  • Lavalle, Luca
  • Fumero, Cecilia
  • Rodriguez-Garcia, Paula
  • Moll, Janne Marie
  • Silva-Zolezzi, Irma
  • Zemrani, Boutaina
  • Hays, Nicholas P.
  • Sprenger, Norbert
  • Miranda-Mallea, Javier
Background and aims Gut health and microbiome development are closely linked in early life, with human milk oligosaccharides (HMOs) playing a key role. This study reports results through 4 months of age from a trial evaluating an infant formula containing a synbiotic blend of HMOs and probiotics, focusing on growth, gastrointestinal (GI) tolerance, and gut health biomarkers from birth to 15 months. Materials and methods Healthy infants aged ≤14 days were randomized to receive either the experimental formula (SYN; control formula supplemented with six HMOs and two probiotics [B. infantis, B. lactis]) or the control formula (CTRL; partially hydrolyzed 100% whey-based formula). A non-randomized breastfed (BF) group served as a reference. The primary endpoint was weight gain velocity in SYN vs. CTRL through 4 months of age. Secondary endpoints included fecal outcomes (abundance of bifidobacteria, immune and gut health markers), GI tolerance, and adverse events (AEs). Results: The full analysis set (FAS) included 313 infants (118 in SYN, 114 in CTRL, and 81 BF), while the per-protocol population (PP) included 227 infants (84 in SYN, 84 in CTRL, and 59 BF). Weight gain velocity through 4 months in the SYN group was non-inferior to that in the CTRL group in both FAS and PP analyses (both p < 0.0001). Parent-reported GI tolerance and stool patterns were similar between SYN and CTRL groups through 4 months. At 3 months, Bifidobacteria abundance was significantly higher in the SYN group compared to the CTRL group (p = 0.004). Fecal pH was lower in the SYN group than in the CTRL group (p = 0.018) and more closely resembled that of the BF group. Immune and gut health markers were similar between the SYN and BF groups. No significant differences in AEs were observed across groups. Conclusion: The synbiotic-supplemented infant formula supported healthy, age-appropriate growth, good GI tolerance, and increased the abundance of beneficial bifidobacteria through 4 months of age., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/31122
Publicación Otros (Other)

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

  • Capdevila, Jaume
  • Pubul, Virginia
  • Anido, Urbano
  • Walter, Thomas
  • Molina-Cerrillo, Javier
  • Alonso-Gordoa, Teresa
  • Garcia-Carbonero, Rocio
  • San-Roman-Gil, Maria
  • Llana, Belen
  • Jimenez-Fonseca, Paula
  • Benavent-Viñuales, Marta
  • Ansquer, Catherine
  • Baudin, Eric
  • Lepage, Come
  • Olmo-Garcia, Maribel-del
  • Ruffinelli, Jose-Carlos
  • Beron, Amandine
  • Haissaguerre, Magalie
  • Deshayes, Emmanuel
  • Taïeb, David
  • Baldari, Sergio
  • Sansovini, Maddalena
  • Cingarlini, Sara
  • Filice, Angelina
  • Panzuto, Francesco
  • Alvarez-Alvarez, Rosa
  • Lousberg, Laurence
  • Aboubakar-Nana, Frank
  • Hernando, Jorge
  • Garcia-Alvarez, Alejando
  • Garcia-Burillo, Amparo
  • Villacampa, Guillermo
  • Vandamme, Timon
  • Fazio, Nicola
  • Durand, Alice
Everolimus is the only approved therapy for patients with advanced neuroendocrine tumors (NET) of lung and thymus and new treatment options are urgently needed. Expression of somatostatin receptor 2 (SSTR2) is frequently seen in functional imaging in lung-NETs opening the opportunity to treat SSTR2 positive patients with radioligand therapies (RLT). Retrospective data suggest a potential meaningful benefit of RLT directed to SSTR2 in lung-NET patients. The LEVEL trial is a randomized, open-label, phase III international trial of 177Lu-edotreotide versus everolimus in patients with progressive, locally advanced or metastatic, and well/moderately differentiated NETs of lung (typical/atypical) or thymic origin. Patients could be treatment-naïve or have progressed (PD) on somatostatin analogues or ≤ 2 additional systemic treatments. Prior RLT or mTOR inhibitors are not permitted. Eligible patients are randomly assigned 3:2 to 6 cycles of 177Lu-edotreotide (total administered activity 7.5 ± 0.7 GBq / cycle) or to oral everolimus 10 mg once daily until PD or unacceptable toxicity. Only patients with positivity in somatostatin receptor imaging will be included. CT or MRI scans are performed every 12 weeks until PD. Blood samples are analyzed at baseline, at 1st tumor assessment, and at PD for pharmacodynamic endpoints. Archival tumor tissue samples will be analyzed for ancillary studies. The primary endpoint is progression-free survival (PFS) according to RECIST v1.1 based on local investigator assessment. Secondary endpoints include overall survival, overall response rate, safety, and quality of life (EORTC QLQ-C30). The expected sample size is 120 patients to demonstrate statistical significant risk reduction of 46.4% (HR = 0.536) in PFS with the experimental treatment using an overall 5% two-sided alpha error with 80% power. An interim PFS analysis was included using the Lan-DeMets with O'Brian-Fleming-like boundaries. The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus. EU CT: 2022-502154-13-00 / www. gov : NCT05918302 (June 23rd, 2023)., Si
Buscador avanzado